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Common strains of lactate dehydrogenase-elevating virus (LDV, an arterivirus), such as LDV-P and LDV-vx, are highly
resistant to antibody neutralization and invariably establish a viremic, persistent, yet asymptomatic, infection in mice. Other
LDV strains, LDV-C and LDV-v, have been identified that, in contrast, are highly susceptible to antibody neutralization and are
incapable of a high viremic persistent infection, but at the same time have gained the ability to cause paralytic disease in
immunosuppressed C58 and AKR mice. Our present results further indicate that these phenotypic differences represent
linked properties that correlate with the number of N-glycosylation sites associated with the single neutralization epitope on
the short ectodomain of the primary envelope glycoprotein, VP-3P. The VP-3P ectodomains of LDV-P/vx possess three
N-glycosylation sites, whereas those of LDV-C/v lack the two N-terminal sites. We have now isolated four independent
neutralization escape variants of neuropathogenic LDV-C and LDV-v on the basis of their ability to establish a high viremic
persistent infection in mice. The VP-3P ectodomains of all four variants had specifically regained two N-glycosylation sites
concomitant with decreased immunogenicity of the neutralization eptitope and decreased sensitivity to antibody neutraliza-
tion as well as loss of neuropathogenicity. © 2000 Academic PressINTRODUCTION
Lactate dehydrogenase-elevating virus (LDV) of mice
is a member of the Arteriviridae family, which also in-
cludes equine arteritis virus (EAV), porcine reproductive
and respiratory syndrome virus (PRRSV), and simian
hemorrhagic fever virus (Cavanagh, 1997; Plagemann,
1996). LDVs have been isolated from laboratory mice
carrying numerous different transplantable tumors which
became contaminated accidentally by passage through
an infected mouse. Many of the original isolates, such as
LDV-PLA (Brinton-Darnell and Plagemann, 1975) and
LDV-RIL (Riley et al., 1960) have been found to be mix-
tures of two slightly different quasispecies, designated
LDV-P and LDV-vx, which have been biologically cloned
by repeated end point dilutions in mice (Chen and Plage-
mann, 1997; Chen et al., 1997, 1998). These LDVs cause
only an asymptomatic, but lifelong persistent viremic
infection in mice. The persistent infection is maintained
by continuous rounds of cytocidal replication in a renew-
able subpopulation of macrophages, in spite of humoral
and cellular anti-LDV immune responses. In fact, repli-
cation of these LDVs is completely resistant to host
immune responses since it is the same in nude or toler-
ized mice as in their immunocompetent littermates and
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8in the persistent phase seems only determined by the
rate of generation of new permissive macrophages
(Plagemann et al., 1995).
The question of how the replication of these LDVs in
permissive macrophages escapes control by the im-
mune responses of the host has been answered by our
studies of two laboratory mutants of LDV (designated
LDV-C and LDV-v) that can, in addition to macrophages,
infect the anterior horn neurons of C58 and AKR mice,
leading to generally fatal paralytic disease (age-depen-
dent poliomyelitis; ADPM; Anderson et al., 1995; Murphy
et al., 1987). The neuropathogenic LDV isolates have
been found to be about 100 times more susceptible to
antibody neutralization than LDV-P/vx and neutralizing
antibodies become generated much more rapidly and to
higher levels in LDV-C/v- than LDV-P/vx-infected mice
(Chen et al., 1999). Selective suppression of the replica-
tion of LDV-C/v by antibody neutralization explains the
finding that these LDVs cause paralytic disease only in
immunosuppressed C58/AKR mice (Murphy et al., 1987;
Anderson et al., 1995; Chen et al., 1999) and their inability
to establish high viremic persistent infections in immu-
nocompetent mice, such as are observed for LDV-P/vx
(Chen et al., 1997, 1998). That the suppression of LDV-C/c
replication in immunocompetent mice was due to anti-
body neutralization was indicated by the finding that in
mice incapable of a humoral immune response, such as
SCID and B-cell-deficient mice, LDV-C/v established per-8
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89LDV AND POLYLACTOSAMINOGLYCAN CHAINSsistent infections with high viremia, just as LDV-P/vx, and
that viremia in these mice decreased about 4 log10 infec-
tious units within 5 h of passive administration of neu-
tralizing antibodies (Chen et al., 1999), a treatment that
had no effect on LDV-P/vx viremia (Plagemann et al.,
1995; Chen et al., 1999). The present study provides
dditional support for these conclusions and genetically
inks the phenotypic properties of the neuropathogenic
DVs to the loss of two of three N-glycosylation sites that
re present in the short (about 30 amino acids long)
ctodomain of the primary envelope glycoprotein (VP-3P)
f the non-neuropathogenic LDVs, which carries the sin-
le neutralization epitope of LDV and is involved in host
eceptor interaction (Faaberg and Plagemann, 1995; Li et
l., 1998). One line of evidence is that the neuropatho-
enic LDV-v is a genetic recombinant of the non-neuro-
athogenic LDV-vx that has specifically acquired a seg-
ent (about 400 nt long) of ORF 5 of LDV-C encoding the
P-3P ectodomain and thereby the phenotypic properties
f LDV-C (Li et al., 1999). In the present study, we have
solated four independent neutralization escape variants
f LDV-C/v that have regained the ability of high viremic
ersistent infection concomitant with loss in neuropatho-
enicity and regaining two N-glycosylation sites on the
ctodomains of their VP-3Ps.
The results strongly support our hypothesis that the
esistance of the non-neuropathogenic LDVs to the hu-
oral immune response of the host is due to the block-
ge of its single neutralization epitope by N-glycans,
hich at the same time prevent interaction of these LDVs
ith an alternate receptor on motor neurons of C58/AKR
ice that is recognized by the neuropathogenic LDVs.
FIG. 1. Time courses of viremia in FVB mice infected with cloned L
antibody production (C) in FVB mice infected with cloned LDV-v when
of two or more infected mice at the indicated times pi and assayed for
(five) were injected ip with LDV-v within 1 day of birth and five other pu
pooled plasma or individual plasma samples were assayed for infec
ynthetic peptide ORF 5-P5 (C). Only the ELISA values of the 1:200 plaRESULTS
he replication of neuropathogenic LDVs is
electively suppressed by neutralizing antibodies
Figure 1A summarizes the difference between non-
europathogenic LDV-P and LDV-vx and the neuropatho-
enic LDV-C and LDV-v in their ability to establish viremic
ersistent infections in mice. Productive replication in
he permissive subpopulation of macrophages during
he first day postinfection (pi) was similar for both LDV
lasses, as indicated by comparable 1-day plasma titers
see also Chen et al., 1997, 1998). Thereafter, the level of
iremia of LDV-P/vx decreased to a relatively constant
evel of between 105 and 107 ID50/ml plasma (Fig. 1A),
which persists for the life of the animals (Plagemann,
1996; Plagemann and Moennig, 1992). In contrast, the
level of viremia of LDV-C and LDV-v continued to de-
crease progressively to a level (102–103 ID50/ml) 10
3–104
ID50 lower than those observed in LDV-P/vx-infected
mice (Chen et al., 1997, 1998; Fig. 1A). We have already
demonstrated that this difference in persistent viremia
does not reflect the replication of the two classes of LDV
in different subpopulations of macrophages (Chen et al.,
1998). In fact, LDV permissive macrophages accumulate
in LDV-C/v-infected mice. The latter have escaped infec-
tion by these LDVs but can be infected in vivo by LDV-P
(Chen et al., 1997, 1998; and see later).
In contrast, in five pups that were tolerized to LDV-v by
infection as newborns (Rowland et al., 1994) and did not
generate a neutralizing antibody response (Fig. 1C), a
high level of viremia persisted, which was comparable to
that in LDV-P/vx-infected mice (cf Figs. 1A and 1B) or in
vx, -C, and -v (A) and time courses of viremia (B) and of neutralizing
orn (T0) or at 22 days of age. In A, plasma was obtained from groups
us virus by mouse titration. In B and C, the pups of one half of a litter
n 22 days of age. The mice were bled at intervals thereafter and their
DV (B) and for neutralizing antibodies by indirect ELISA (A405) using
ilution are shown.DV-P, -
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90 CHEN, LI, AND PLAGEMANNSCID and B-cell-deficient mice infected with LDV-C/v
(Chen et al., 1999). The five pups from the same litter that
were infected with LDV-v only at 22 days of age gener-
ated a normal neutralizing antibody response (Fig. 1C)
and LDV-v replication was concomitantly suppressed
(Fig. 1B). The importance of the results with the tolerized
mice is that they show that the ability of LDV-C/v to
establish a high viremic persistent infection is specifi-
cally due to the absence of anti-LDV antibodies and not
to some general immunodeficiency of the mice. LDV
neutralizing antibodies were measured (Fig. 1C) by bind-
ing to a synthetic peptide representing the ectodomain of
VP-3P of LDV-C/v that contains the neutralization epitope
(ORF-5-P5; Li et al., 1998). Neutralizing antibodies be-
came generated very rapidly in the pups infected at 22
days of age, attaining a maximum titer by 4 weeks pi (Fig.
1C), as is typical for LDV-C/v-infected mice (Li et al., 1998;
Chen et al., 1999), whereas in LDV-P/vx-infected mice the
generation of low levels of neutralizing antibodies is
delayed for 3–4 weeks (Rowson and Mahy, 1975; Cafruny
et al., 1986; Chen et al., 1999).
In attempts to isolate neutralization escape variants of
the neuropathogenic LDVs (see later), we initially moni-
tored viremia in a total of 12 LDV-C- or LDV-v-infected
FVB mice. Viremia persisted at a very low level (102–103
ID50/ml of plasma) past 100 days pi, indicating failure of
he immune system to completely clear the virus (see
ater). However, in one LDV-C-infected mouse, virus
ould no longer be detected by the biological assay (Fig.
A) or a reverse transcription–polymerase chain reaction
RT–PCR) assay (Fig. 2B) at 70–110 days pi. Treatment of
FIG. 2. LDV clearance in a long-term LDV-C-infected FVB mouse. A
mouse infected with cloned LDV-C was bled at intervals and its plasma
assayed for infectious LDV (F—F; —) and for antibodies that
bound to the neutralizing epitopes of LDV-P (ORF 5-P3) and LDV-C/v
(ORF 5-P5); (E—E; —, respectively). Only the ELISA values (A405) of
the 1:200 dilution of plasma are plotted. At 92 days pi, the mouse was
injected with cyclophosphamide (CY; 200 mg/kg body weight). Also as
indicated by arrows the mouse was injected with 106 ID50 of cloned
LDV-C or 106 ID50 of LDV-P; F_ indicates that no LDV was detected in the
owest plasma dilutions tested (e.g., 1022 at 64 and 79 days pi and 1021
at 92, 106, 115, 120, and 128 days pi) and that the virus titer therefore
was equal to or below the plotted value.he mouse at 98 days pi with cycloposphamide, which
enerally enhances LDV viremia in persistently infected
ice 10- to 100-fold (see later) did not result in detectable
iremia, making it unlikely that the mouse harbored re-
idual LDV at a level not detectable by the assays em-
loyed. This is the first time a mouse has been shown to
ave cleared an LDV infection. Furthermore, two sequen-
ial superinfections of the mouse with 106 ID50 of cloned
DV-C did not result in detectable LDV replication (Fig.
A). Thus, the mouse was completely resistant to super-
nfection by LDV-C. In contrast, after superinfection with
loned LDV-P the plasma titer had increased to 107
ID50/ml 1 day later, even though the mouse possessed
ntibodies that bound in an ELISA to the synthetic pep-
ides carrying the neutralization epitopes of either LDV-
/v (ORF5-P5) or LDV-P (ORF 5-P3; Fig. 2A). Thereafter
iremia leveled off at a level typical for mice persistently
nfected with LDV-P. Differential RT–PCR confirmed that
nly the LDV-P genome was present in the mouse 1 day
fter superinfection with LDV-P (Fig. 2B). The results
onfirm that the cured mouse possessed LDV-permis-
ive macrophages and that, in contrast to the neuro-
athogenic LDV-C, the replication of non-neuropatho-
enic LDV-P in vivo was resistant to the action of anti-
LDV immune responses.
Neuropathogenicity and increased immunogenicity
and sensitivity to antibody neutralization of LDVs
correlate with loss of two N-glycosylation sites
associated with the neutralization epitope
on the ectodomain of VP-3P
In previous studies we demonstrated that neutralizing
monoclonal anti-LDV antibodies react similarly with the
unmodified synthetic peptides representing the neutral-
ization epitopes of neuropathogenic LDV-C/v and non-
neuropathogenic LDV-P and LDV-vx (Li et al., 1998). This
was also the case for the neutralizing antibodies gener-
ated in LDV-C-infected mice (Fig. 2A). Thus the slight
amino acid differences between the VP-3P ectodomains
of the neuropathogenic and non-neuropathogenic LDVs
(see Fig. 3) per se cannot account for their differences in
immunogenicity and sensitivity to antibody neutraliza-
tion. The only consistent differences we have detected
between the predicted VP-3Ps of the various LDV iso-
lates that correlated with neuropathogenicity and im-
paired ability to establish a high viremic persistent infec-
tion (due to increased sensitivity to antibody neutraliza-
tion; see earlier) was that the ectodomains of VP-3P of
the neuropathogenic LDVs (LDV-C/v) lacked two of three
N-glycosylation sites that are associated with those of
the non-neuropathogenic LDVs (LDV-P/vx; Chen et al.,
1998; see Fig. 3). Since other results suggest that all
three N-glycosylation sites of the VP-3P ectodomain of
LDV-P are occupied by N-glycans (see Discussion), we
postulated that the latter may protect the neutralization
epitope of LDV-P/vx from antibody binding and lower its
91LDV AND POLYLACTOSAMINOGLYCAN CHAINSimmunogenicity and that the loss of the two N-terminal
chains is required to allow LDV to interact with a putative
alternate receptor on anterior horn neurons of C58 and
AKR mice while at the same time rendering the neutral-
ization epitope more immunogenic and more accessible
to antibody binding (Chen et al., 1998, 1999).
In order to obtain further evidence in support of this
hypothesis, we have attempted to obtain mutants of the
neuropathogenic LDVs that were able to sustain a high
viremic persistent infection. A total of 12 mice were
infected with LDV-C or LDV-v in different experiments
and their plasma LDV titers determined in 1- to 3-week
intervals. In many cases, plasma obtained at 80–160
days pi was injected into new mice, and their viremia
FIG. 3. Comparison of the amino acid sequences of the ORF 5 prot
Fig. 4 and text) with those of LDV-P, LDV-vx, LDV-C, and LDV-v. The pr
N-glycosylation sites in the ectodomain are shown in boldface letters.
Accession No. U15146) and Godeny et al. (1993; GenBank Accession No
GenBank Accession Nos. AF092282 and AF092283, respectively). Th
indicated by periods.was similarly monitored. Eventually, viremia increased in
a total of four mice. Figures 4A–4C illustrate results from
one such experiment with LDV-v. While in one of two
mice originally infected with LDV-v viremia remained at a
very low level, viremia in the second mouse began to
increase about 60 days pi, reaching a level only slightly
lower than that normally observed in mice persistently
infected with LDV-P/vx (see Fig. 1A) in spite of the pres-
ence of high levels of antibodies that bound to the neu-
tralization epitope of LDV-v (ORF 5-P5; data not shown;
see Fig. 2A). Upon passage of the LDV-v variant at 105
days pi to new mice it established a persistent infection
similar to that in the mouse in which it emerged (Figs. 4A
and 4B). Differential RT–PCR showed that the genome of
-3P) of four “neutralization escape” mutants of LDV-C and LDV-v (see
signal peptide and transmembrane segments are overlined and the
quences for LDV-P and LDV-C are from Palmer et al. (1995; GenBank
8), respectively and those for LDV-v and LDV-vx are from Li et al. (1999;
P ectodomain of LDV-v-T105/38 contains a two-amino-acid deletioneins (VP
oposed
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92 CHEN, LI, AND PLAGEMANNthe variant was still LDV-C/v-like (Fig. 4C; T93) and that
the increase in viremia was therefore not due to super-
infection by LDV-P or LDV-vx. Sequence analysis of ORF
5 of the variant (isolated at 38 days pi and designated
LDV-v T105/38) showed that the ectodomain of its VP-3P
had specifically regained two N-glycosylation sites, one
at the same position as that in the VP-3P ectodomain of
LDV-P/vx, but an N-terminal one at a new site (Fig. 3). The
remainder of the ORF 5 protein sequence of LDV-v-
T105/38 clearly indicated that it was a mutant of LDV-v;
only six additional amino acid differences were ob-
served, two in the signal peptide, two in the ectodomain,
and two between transmembrane segments 2 and 3 (Fig.
3). However, ORF 5 of LDV-v-T105/38 also carried a 6-nt
deletion which resulted in a two-amino-acid deletion at
the C-terminal end of the VP-3P ectodomain (Fig. 3).
Two similar neutralization escape variants (LDV-C-T82/
68H/76 and LDV-C-T82/110N/76; Fig. 4E) were derived
from mice originally infected with cloned LDV-C. Plasma
obtained from two LDV-C-infected mice at 82 days pi with
a titer of 102.5 ID50/ml was injected into two new mice (H
and N; Fig. 4D) and from these mice again to three new
mice at 68 and 110 days pi, respectively (Fig. 4E). Both
groups of mice exhibited increased viremia. Differential
RT–PCR documented that the LDVs present at 76 days pi
were still LDV-C-like (Fig. 4F) and sequence analysis of
their ORF 5 showed that the ectodomains of the VP-3Ps
of these LDVs had also regained two N-glycosylation
sites (Fig. 3); in this case the new N-terminal sites were
at the same position as that in the VP-3P ectodomain of
LDV-P/vx. Nevertheless, the VP-3P sequences indicated
that both variants were clearly mutants of LDV-C (Fig. 3).
FIG. 4. Isolation of variants of LDV-C and LDV-v that exhibited an incre
ith cloned LDV-v were bled at intervals and their plasma titers determi
viremia (F—F) at 105 days pi (LDV-v-T105) and injected into two new
from these latter mice at 38 days pi (LDV-v-T105/38) and the sequence
the infected mice at 93 days pi was analyzed by ORF 4/5-specific diff
obtained from two mice that had been infected for 82 days with cloned
monitored for viremia (F—F). ORF 5 of viruses isolated from pooled
LDV-C-T82/68H) was sequenced (see Fig. 6). Furthermore, plasma from
ays pi, respectively, were each injected into groups of three new
espectively). Viruses were isolated from these mice at 76 days pi and
equenced (Fig. 3).A fourth neutralization escape variant (LDV-C-T168/55)
was derived in a similar manner from another LDV-C-
infected mouse (data not shown). The ectodomain of its
VP-3P also had regained two N-glycosylation sites, but in
this case the N-terminal site was also located in a new
position, just as in the VP-3P ectodomain of LDV-v-
T105/38 (Fig. 3). The VP-3Ps of all four variants differed in
additional amino acids from the VP-3Ps of LDV-C/v, be-
sides regaining two N-glycosylation sites, but these di-
vergent amino acids were at different locations, so that
they could not account for the increased ability to estab-
lish a viremic persistent infection.
The neutralization escape variants were cloned by end
point dilution in mice, as described previously (Chen et
al., 1997, 1998), and their growth patterns and the neu-
tralizing antibody responses of their hosts were moni-
tored. The viremia patterns of the cloned mutants were
similar to those shown in Figs. 4B and 4E. Although the
level of viremia varies somewhat between mice (Plage-
mann, 1996), overall the persistant viremia of the LDV-C
neutralization escape mutants was about 1log10ID50
lower than that observed for LDV-P/vx. This lower viremia
does not seem to be due to antibody neutralization since
these mutants exhibited the same high resistance to in
vitro antibody neutralization as the non-neuropathogenic
LDVs (data not shown; see Chen et al., 1999). Further-
more, the production of neutralizing antibodies in mice
infected with the four mutants of LDV-C and LDV-v, like
that in LDV-P/vx-infected mice, was delayed about 3
weeks, at which time the level of neutralizing antibodies
had already reached close to a maximum in companion
mice infected with the parent LDV-C and LDV-v (Fig. 2C).
bility to establish a viremic persistent infection. In A, two mice infected
E; F—F). Plasma was obtained from the mouse showing increased
he recipient mice were monitored for viremia (B). Virus was obtained
ORF-5 was determined (see Fig. 3). In addition, plasma obtained from
l RT–PCR (C: T93). In D, two mice were injected with pooled plasma
and exhibited a plasma titer of 102.5 ID50/ml. The recipient mice were
at 20 days pi (LDV-C-T82/20) and from one mouse (H) at 68 days pi
ouse (H) and that of the other mouse (N) obtained at 68 days and 110
nd these mice were also monitored for viremia (E; —, —,
ed by ORF 4/5-specific differential RT–PCR (F) and their ORF-5s wereased a
ned (E—
mice. T
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93LDV AND POLYLACTOSAMINOGLYCAN CHAINSThe latter results indicate that regaining of the two N-
glycosylation sites on the VP-3P ectodomains of the
neutralization escape mutants resulted in lowering the
immunogenicity of their neutralization epitopes. The
lower persistant viremia of mice infected with the LDV-C
mutants probably reflects a decreased ability to replicate
in newly generated macrophages, compared to that of
LDV-P, since they, like the parent LDV-C, were rapidly
outcompeted by LDV-P in mixed infections, even in mice
incapable of anti-LDV immune responses (unpublished
data). The molecular basis of this difference is not
known.
The cloned neutralization escape variants were also
examined for neuropathogenicity by injecting groups of
three immunosuppressed 2-month-old C58 mice with
about 106ID50 of virus. The mice were immunosup-
pressed by injection of 200 mg cyclophosphamide at 21,
7, and 14 days pi (Anderson et al., 1995). None of the
mice injected with the neutralization escape mutants
developed paralytic symptoms, whereas all three com-
panion mice injected with cloned LDV-v became para-
lyzed, with a mean onset of 17.7 days pi. These results
support the conclusion that neuropathogenicity, sensitiv-
ity to antibody neutralization, and immunogenicity of the
neutralization epitope are closely linked properties that
are determined by the number of N-glycans associated
with the VP-3P ectodomain.
However, the appearance of such non-neuropatho-
genic “neutralization escape variants” in vivo was not an
invariable event; it occurred in only 4 mice of a total of 12
LDV-C/v-infected mice whose long-term viremia was ini-
tially monitored. As discussed already, 1 LDV-C-infected
FIG. 5. Failure of appearance of neutralization escape variants during
mouse was monitored for viremia and injected with cyclophosphamide
at 163 days pi was injected into two new mice (H, HT) and the mice
harvested from the HT and H mice at 99 and 143 days pi, respectively,
for viremia for 103 days (data not shown, see text). Furthermore, the Omouse became cured (Fig. 2), but in all the other mice
LDV-C or LDV-v continued to persist at a very low level
(see Fig. 4A). Furthermore, the LDVs obtained from sev-
eral LDV-C- or LDV-v-infected mice with low persistent
viremia were passaged twice in new mice, each time for
50–100 days, without an increase in persistent viremia or
only a marginal one (data not shown). The low frequency
of generation of neutralization escape variants was not
entirely unexpected considering the low level of replica-
tion of LDV-C/v in these mice during the persistent
phase. Since 1 ID50 represents at best several infectious
virions (Plagemann, 1996), probably not more than a few
hundred virions are produced per day in the long-term
LDV-C/v-infected mice, which could be provided by in-
fection of a single macrophage per day.
In order to increase the availability of LDV permissive
macrophages during the persistent infection we have
treated LDV-C/v-infected mice with cyclophosphamide.
We have shown previously that such treatment results in
an increased generation of LDV permissive macro-
phages, which allows increased virus replication (Row-
land et al., 1994). Cyclophosphamide, however, also
strongly inhibits anti-LDV antibody production, but since
the half-life of preexisting neutralization antibodies was
found to be only about 5 days (unpublished data), we
reasoned that the replication of neuropathogenic LDVs
could be transiently increased as a result of cyclophos-
phamide treatment without significantly affecting the se-
lective pressure exerted by antibody neutralization. An
example of this type of experiment is illustrated in Fig. 5.
An FVB mouse infected with cloned LDV-C was treated
with cyclophosphamide at 148 and 155 days pi, which
long-term infections of FVB mice with cloned LDV-C. An LDV-C-infected
e2; 200 mg/kg body weight) at 148 and 153 days pi. Plasma obtained
injected with CY as indicated and monitored for viremia (B). Plasma
jected into groups of three mice and these mice were also monitored
of the indicated isolates were sequenced (see Fig. 6).some
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94 CHEN, LI, AND PLAGEMANNresulted in an increased viremia (Fig. 5A), though sub-
sequently viremia decreased again to a low level. At 163
days pi virus was isolated from the mouse and injected
into two new mice, which were then monitored for vire-
mia and also treated at intervals with cyclophosphamide.
One mouse (HT) died at 99 days pi after bleeding. The
viruses harvested from this mouse and from its compan-
ion mouse (H) at 111 days pi were injected into groups of
new mice but in all mice viremia decreased to 102.5–103.0
ID50/ml of plasma (data not shown). Thus no neutraliza-
ion escape variant arose in this set of mice during over
year of propagation of the virus.
However, in this and other experiments we have de-
ected mutants of LDV-C whose VP-3P ectodomain had
cquired one or two N-terminal N-glycosylation sites
see Fig. 6) without gaining in ability to establish a vire-
ic persistent infection. For example, in the experiment
epicted in Fig. 4D ORF 5 sequence analysis (Fig. 6)
ndicated the presence of a mutant of LDV-C at 20 days
i (LDV-C T82/20) whose VP-3P ectodomain had gained
he N-terminal N-glycosylation site present in the VP-3P
ctodomain of LDV-P/vx. Sequence analysis of one ORF
clone of the virus present at 68 days pi (LDV-C T82/
8H-1) indicated the presence of the same mutant, but a
econd clone of the virus yielded a wild-type LDV-C
equence (Fig. 6). But, as already discussed, after trans-
er of these viruses to new mice mutants grew out whose
P-3P ectodomains possessed both the N-terminal and
he middle N-glycosylation sites (Figs. 3 and 4E). In the
xperiment depicted in Fig. 5, ORF 5 sequence analysis
lso indicated the presence of mutants whose VP-3P
FIG. 6. Comparison of the amino acid sequences of the ectodomains
urtaugh et al., 1995), of a number of representative North American
apur et al., 1996; Mardassi et al., 1995; Meng et al., 1994), of the Europ
of a number of variants of LDV-C that have been cloned via RT–PCR fro
are from the experiment depicted in Fig. 4D (1 and 2 refer to different TA
experiment depicted in Fig. 5. LDV-C-T140HT,-T18/64-1, and -T18/64-2 w
of the signal peptide and the N end of the first postulated transmembr
all PRRSV and LDV isolates as well as the common N-glycosylation sctodomains had gained N-terminal N-glycosylation
ites (Fig. 6; LDV-C T163, T163/99HT, and T163/111H). In
act the VP-3P ectodomain of one variant (LDV-C T163)
ossessed two adjacent N-terminal N-glycosylation
ites. These variants, however, became later lost, since
t 59 days pi in the third passage only wild-type LDV-C
as detected (LDV-C T163/143/59). Similarly, in two other
xperiments variants were detected whose VP-3P
ctodomains had acquired N-terminal N-glycosylation
ites (LDV-C-T140 HT and LDV-C-T18/64-1) without lead-
ng eventually to the generation of mutants with in-
reased ability to establish a viremic persistent infection.
f mutants with increased resistance to antibody neutral-
zation had arisen, viremia would have increased and the
utants would rapidly have outgrown the parent LDV-C.
he results indicate that acquisition of one or two N-
erminal N-glycosylation sites resulted in little, if any,
ncreased ability for viremic persistence or to outcom-
ete the parent LDV-C. These abilities strictly correlated
ith the acquisition of the middle N-glycosylation site in
ddition to an N-terminal one. Thus it seems likely that
he middle polylactosaminoglycan chain on the VP-3P
ctodomain is the most important one in preventing
ntibodies from binding to the neutralization epitope.
owever, we have not detected a single clone that had
cquired the middle N-glycosylation site on the VP-3P
ctodomain without not also possessing an N-terminal
ne (Fig. 3). But, we found that one clone, T18/64-2,
ossessed a VP-3P with an amino acid change that
esulted in the loss of the C-terminal N-glycosylation site
Fig. 6).
RF 5 proteins of the prototype North American PRRSV isolate (VR2332;
field isolates with different glycosylation patterns (IA1, IL1, MN1, NE1;
olate of PRRSV (LV; Muelenberg et al., 1993), and of LDV-P, LDV-C, and
-term LDV-C-infected mice. LDV-C-T82/20, -T82/68H-1, and -T82/68H-2
s). LDV-C-T163, -T163/99HT, -T163/99HT, and -T163/143/59 are from the
lated from other LDV-C, infected mice in similar experiments. The end
gment are overlined. Asterisks indicate the Cys residue conserved inof the O
PRRSV
ean is
m long
clone
ere iso
ane se
ite.
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95LDV AND POLYLACTOSAMINOGLYCAN CHAINSAttempts to isolate neutralization escape variants of
LDV-C by incubating 108–109 ID50 with anti-LDV antibod-
ies in vitro and then growing up the residual nonneutral-
ized virus in mice were unsuccessful. The virus isolated
after 11 such treatments was still unable to establish a
high viremic persistent infection and ORF 5 sequence
analysis indicated that it belonged to the LDV-C quasi-
species (data not shown).
DISCUSSION
Combined, the results from our earlier and present
studies prove that the impaired ability of the neuropatho-
genic LDVs to establish a high viremic persistent infec-
tion is due to selective antibody neutralization. In mice
that fail to generate anti-LDV antibody responses, either
because of a genetic defect or tolerization, both cloned
LDV-C and LDV-v establish high viremic persistent infec-
tions (Fig. 1B; Chen et al., 1999) similar to those observed
for the non-neuropathogenic LDVs, whose persistent
replication is impervious to all host defenses. Also, pas-
sive administration of neutralizing antibodies effectively
suppresses viremia in LDV-C-infected SCID mice (Chen
et al., 1999). Two factors are responsible for the selective
suppression of the replication of the neuropathogenic
LDVs by the humoral immune response: an increased
immunogenicity of the neutralization epitope of the neu-
ropathogenic LDVs that results in a more rapid genera-
tion of neutralizing antibodies and of higher levels than
observed for the non-neuropathogenic LDVs and an in-
creased sensitivity of the neuropathogenic LDVs to anti-
body neutralization (Fig. 2A; Chen et al., 1999).
However, in spite of effective suppression of the rep-
lication of the neuropathogenic LDVs in immunocompe-
tent mice, the mice most often fail to completely clear the
infection for at least several months (Chen et al., 1997,
998; see Figs. 4 and 5). But since the replication of the
europathogenic LDVs in the permissive macrophages
f these mice is strongly inhibited by antibodies, clear-
nce of lactate dehydrogenase (LDH) may eventually
eturn to close to normal (Chen et al., 1999). Thus, phe-
otypically, these mice resemble normal uninfected
ice. It is unclear how this very low level persistence is
aintained. It might require the productive infection of
nly a single macrophage/day since the yield of LDV/
acrophage is about 104 ID50 (Plagemann, 1996). These
acrophages are probably infected by nonneutralized
irions, but infection via FC receptors by LDV–immune
omplexes has not been ruled out since such infection
an occur in vitro (Cafruny and Plagemann, 1982). It is
lso possible that the macrophages that sustain a low-
evel persistent infection are located in tissues not
eadily accessible to antibodies. Nonetheless, one
ouse completely cleared LDV-C by 3 months pi (Fig. 2).
Our results also demonstrate convincingly that neuro-
athogenicity, immunogenicity of the neutralization
pitope, and sensitivity to antibody neutralization arelosely linked properties and are determined by the
umber of N-glycosylation sites on the short ectodomain
f the primary envelope glycoprotein VP-3P (encoded by
RF 5). This very short ectodomain (about 30 amino
cids long) seems involved in host receptor recognition
Faaberg and Plagemann, 1995; Faaberg et al., 1995) and
arries the LDV neutralization epitope (Li et al., 1998).
In the non-neuropathogenic LDV-P and LDV-vx and
our other LDVs we have isolated from wild house mice
he VP-3P ectodomain contains three N-glycosylation
ites (Fig. 3). These sites all seem to be occupied by
arge N-glycans, since the molecular weight of VP-3P
solated from LDV-P virions is over twice (up to 50 kDa)
hat predicted by its amino acid content (18–19 kDa after
leavage of the signal peptide; Cafruny et al., 1986;
aaberg and Plagemann, 1995) and since during in vitro
ranslation of ORF 5 of LDV-P in the presence of mem-
ranes all three sites became glycosylated (Faaberg and
lagemann, 1995). We conclude that the N-glycans im-
ede the immunogenicity of the neutralization epitope
nd render these viruses highly resistant to antibody
eutralization. This explains their ability to establish a
igh viremic persistent infection in mice. The same ap-
lies to the neutralization escape mutants we have iso-
ated from the neuropathogenic LDV-C and LDV-v. All four
xhibit decreased immunogenicity of the neutralization
pitope and decreased sensitivity to antibody neutraliza-
ion as well as loss of neuropathogenicity concomitant
ith regaining two N-glycosylation sites on their VP-3P
ctodomains. We have no proof that the VP-3P N-glyco-
ylation sites of the mutants are glycosyated but this
eems likely in view of our results with LDV-P. The middle
olylactosaminoglycan seems to be the primary deter-
inant of at least the high resistance of LDV-P/vx to
ntibody neutralization since we have detected several
ariants of LDV-C/v that had regained an N-terminal
-glycosylation site without gaining the ability to cause a
iremic persistent infection (Fig. 6). The position of the
-glycosylation sites, at least of the middle one, might
lso be an important determinant, since all four neutral-
zation escape mutants had acquired the middle N-gly-
osylation site at the same position as found in the VP-3P
ctodomain of LDV-P/vx (Fig. 3). However, no neutraliza-
ion escape mutants were detected that had acquired
nly the middle N-glycosylation site. Thus, the N-terminal
ite may play a contributing role in determining the phe-
otype properties of these LDVs, although its position
eems to be more flexible (Figs. 3 and 6).
Loss of the two N-terminal polylactosaminoclycan
hains on the VP-3P ectodomain of LDV-C/v enhances
he immunogenicity of the neutralization epitope and
enders these viruses sensitive to antibody neutralization
nd endows them with neuropathogenicity. Linkage of
hese phenotypic properties and localization of the mo-
ecular determinants is also indicated by the finding that
DV-v is a double genetic recombinant of LDV-vx that has
p
c
L
b
a
n
t
m
a
w
s
t
b
(
i
a
o
1
c
N
f
a
a
t
a
c
e
t
t
o
i
s
l
s
e
a
i
l
m
p
h
t
V
s
N
P
i
T
e
u
s
o
t
n
i
v
l
t
A
S
O
m
N
o
t
p
n
f
B
n
c
n
a
M
b
P
i
(
96 CHEN, LI, AND PLAGEMANNspecifically acquired the VP-3P ectodomain of LDV-C and
thereby its phenotypic properties (Li et al., 1999).
The finding that the molecular determinant of neuro-
pathogenicity is located in the ectodomain of VP-3P,
which is implicated in host receptor recognition, sup-
ports our hypothesis that the neuropathogenicity of LDV-
C/v reflects their ability to interact with an alternate
receptor on the anterior horn neurons of C58/AKR mice.
This view is further supported by the finding that LDV cell
tropism is largely determined at the level of host cell
receptor interaction rather than at the level of intracellu-
lar replication (Inada et al., 1993; Plagemann, 1996). The
resence of the two additional polylactosaminoglycan
hains on the VP-3P ectodomains of LDV-P/vx and the
DVs isolated from wild house mice are postulated to
lock their interaction with the alternate receptor on
nterior horn neurons of C58/AKR mice that is recog-
ized by the neuropathogenic LDVs without affecting
heir ability to interact with the receptor on permissive
acrophages. The linkage between neuropathogenicity
nd sensitivity to antibody neutralization also explains
hy LDV-C/v cause paralytic disease only in immuno-
uppressed C58 and AKR mice (Chen et al., 1999).
Protection of epitopes on viral glycoproteins from an-
ibody binding by polylactosaminoglycan chains has also
een reported for the NB protein of influenza B virus
Williams and Lamb, 1988), the HA protein of human
nfluenza A virus (Skehel et al., 1984), the HA protein of
vian influenza virus (Munk et al., 1992), and the V3 loop
f gp120 of human immunodeficiency virus (Back et al.,
994; Papendreov and Fenovillet, 1998). In fact, in the
ase of the HA epitope of avian influenza virus a single
-linked N-glucosamine was sufficient for protecting it
rom antibody binding (Munk et al., 1992), and glycosyl-
tion of the same site affected receptor binding to an
djacent site (Ohuchi et al., 1997). Similarly, egg adapta-
ion of influenza B virus was associated with the loss of
n N-glycosylation site on the distal tip of the HA protein
oncomitant with a change in antigenic properties (Rob-
rtson et al., 1985). However, protection of a single neu-
ralization epitope by N-glycans is unlikely to render
hese viruses resistant to the humoral immune response
f the host, since they possess more than one neutral-
zation epitope. The unique feature of LDV is that it
eems to possess only a single neutralization epitope
ocated on the short ectodomain of VP-3P and that as-
ociation of the three polylactosaminoglycans with this
pitope in LDV-P/vx also impairs epitope immunogenicity
nd makes these LDVs completely resistant to neutral-
zation in vivo, allowing them to invariably establish a
ife-long viremic infection. However, these properties
ay not be unique for LDV and may apply to other
ersistent RNA viruses. Furthermore, the colocation of
ost receptor attachment sites and a sole or major neu-
ralization epitope, such as in the short ectodomain of
P-3P of LDV, may be a common occurrence in viral
tructural proteins (Smith et al., 1997; Weiss, 1996), as isthe modulation of cell tropism and antigenic properties
by polylactosaminoglycans in the case of enveloped
viruses.
The finding that polylactosaminoglycan chains protect
non-neuropathogenic LDVs from antibody neutralization
and impair the immunogenicity of the neutralization
epitope may have implications for PRRSV since the ORF
5 proteins of all PRRSV isolates are very similar in size,
structure, and sequence to that of LDV (Plagemann,
1996). Especially, certain segments in the ectodomain
are identical for all LDVs and for both the European
isolate (LV) and the prototype North American isolate
(VR2332) of PRRSV (Fig. 6), even though the ORF 5
proteins of the latter two differ by about 47%. The Cys
residue that is postulated to link the protein to the matrix
protein, M/VP-2 (Faaberg et al., 1995), and the C-terminal
-glycosylation site are conserved in all LDVs and
RRSVs, including many North American PRRSV field
solates (represented in Fig. 6 by IA1, IL1, MN1, and NE1).
he same is the case for the middle N-glycosylation site,
xcept for the neuropathogenic LDVs, whose VP-3Ps are
niquely lacking this site. Only the N-terminal N-glyco-
ylation site(s) seems variable (Fig. 6). The significance
f the polylactosaminoglycan chains on the ORF 5 pro-
eins of PRRSV with respect protection from antibody
eutralization, however, is still unexplored, but important
n the development of an effective vaccine against this
irus.
The same question arises in the case of SHFV which,
ike LDV, causes only long-term persistent, yet asymp-
omatic, infections in its natural hosts (three genera of
frican monkeys; Plagemann, 1996). The structure of the
HFV envelope glycoprotein equivalent to that of the
RF 5 proteins of LDV and PRRSV predicts an ectodo-
ain of about 100 amino acids, with eight closely spaced
-glycosylation sites (Smith et al., 1997). The ectodomain
f the ORF 5 protein of EAV is also much larger than
hose of LDV and PRRSV, but possesses only a single
olylactosaminoglycan chain which is distal to its single
eutralization epitope(s), located just upstream of the
irst transmembrane segment (den Boon et al., 1991;
alasuriya et al., 1995). The finding that EAV is readily
eutralized by antibodies is thus consistent with our
onclusion that the resistance of LDV-P/vx to antibody
eutralization is due to the association of polylactos-
minoglycan chains with its neutralization epitope.
MATERIALS AND METHODS
ice
FVB mice, including pregnant females, were supplied
y the transgenic facility of the University of Minnesota.
lasma was obtained from mice by the orbital bleed-
ng method using heparinized blood collection tubes
Fischer Scientific, Pittsburg, PA).
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The origins of non-neuropathogenic LDV-P and LDV-vx
and of neuropathogenic LDV-C and LDV-v and their clon-
ing by end point dilution in mice have been described
previously (Chen and Plagemann, 1997; Chen et al., 1997,
1998, 1999).
LDV concentrations were estimated by an end point
dilution assay in FVB mice (Chen and Plagemann, 1997).
The assay is based on the 5- to 10-fold increase in
plasma LDH activity that is invariably associated with an
LDV infection of mice (Plagemann, 1996). LDV titers are
expressed as 50% infectious doses (ID50). LDV stocks
consisted of plasma harvested from single or groups of
mice 1 day after inoculation with about 106 ID50 and
contained 109 to 1010 ID50/ml.
easurement of neutralizing antibodies by indirect
LISA
The procedure was as described previously (Li et al.,
998). In brief, the wells of ELISA plates were coated with
0-amino-acid long synthetic peptides that represent the
ctodomains of VP-3P of LDV-P (ORF 5-P3) or LDV-C/v
ORF 5-P5) and contain the neutralization epitopes of
hese LDVs (Fig. 3). The plates were then sequentially
ncubated with blocking solution, twofold dilutions of
lasma from infected mice (1:50 to 1:1600), alkaline
hosphatase-conjugated goat anti-mouse IgG, and en-
yme substrate. The absorbency of the alkaline phospha-
ase product was measured at 405 nm (A405) with an
automatic microplate reader.
Measurement of in vitro antibody neutralization of LDV
As described previously (Cafruny et al., 1986; Chen et
l., 1999; Plagemann et al., 1992), samples of about 107
ID50 of LDV were incubated in vitro with normal mouse
plasma (NMP) or plasma from LDV-infected mice (IMP).
The residual LDV infectivity in both samples was deter-
mined by titration in mice. The degree of neutralization is
defined as the difference in titer between the samples
incubated with NMP and IMP (in log10 ID50).
Differential RT–PCR assay
We have developed RT–PCR assays that distinguish
the genomes of LDV-C/v from those of LDV-P and LDV-vx
(Chen et al., 1997, 1998). One assay is based on the
finding that a segment in the 59-terminal end of ORF 5 of
LDV-C/v (encoding the signal peptide of the ORF 5 pro-
tein, VP-3P) differs 35 and 30% from the corresponding
segments of LDV-P and LDV-vx, respectively. Antisense
oligonucleotides prepared to these segments (/J1003,
/J1004, and /J1007) were used as primers in combination
with a sense primer (J1008/) to a segment in ORF 4 that
is identical for LDV-C and LDV-P to PCR amplify RT
products of LDV RNA extracted from plasma of infected
mice to yield products of 483 bp. The RT–PCR assay isreproducible and distinguishes the genomes of LDV-C
and LDV-v from those of LDV-P and LDV-vx (Chen et al.,
1998).
LDV genomic RNA was extracted from 4 ml of mouse
plasma using RNAzol and reverse transcribed and the
first strand products were amplified by PCR using the
primer sets cited above, as described previously (Chen
and Plagemann, 1997; Chen et al., 1997, 1998).
ORF 5 sequence analysis
The determination of the sequence of ORF 5 of various
LDV isolates was conducted as described previously
(Chen et al., 1997, 1998). RNA extracted from plasma of
infected mice was reverse transcribed and amplified by
PCR using a sense primer upstream (A1468/) and an
antisense primer downstream (/B1836) of ORF 5 to yield
a product of 688 bp. The amplified PCR products were
cloned into the TA cloning vector pCRII (Invitrogen, San
Diego, CA) and the clones were sequenced on both
strands with Sequenase version 2.0 (U.S. Biochemical
Corp., Cleveland, OH) as described by the manufacturer.
Sequence analyses were performed with the Molecular
Biology Information Resources programs SAM and
EUGENE (Lawrence and Goldman, 1988).
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